Patient characteristics
| Patient . | Sex . | Initial sampling . | Follow-up . | HLA-class I . | EBV IgG . | CMV IgG . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (y) . | Diagnosis . | Disease state . | Current treatment . | Time after initial sample (mo) . | Disease state . | Current treatment . | |||||
| 105 | M | 19 | mAA | PR after ATG + CsA | CsA + Epag | A∗24:02 B∗07:05; B∗51:01 C∗03:04; C∗15:05 | Pos. | Neg. | |||
| 144 | M | 57 | sAA | Relapse after ATG | CsA + Epag | A∗02:01; A∗03:01 B∗07:02; B∗51:01 C∗02:02; C∗07:02 | Pos. | Pos. | |||
| 191 | F | 69 | sAA | Relapse after ATG + Epag | CsA + Epag | 18 | Relapse | CsA + Epag | A∗24:02 B∗07:02 C∗07:02 | Pos. | Pos. |
| 192 | M | 56 | mAA | Relapse after CsA + Epag | Epag | A∗02:01; A∗32:01 B∗07:02; B∗40:02 C∗02:02; C∗07:02 | Pos. | Neg. | |||
| 198 | F | 48 | vsAA | Initial diagnosis | None | 20 | CR | CsA | A∗02:01; A∗33:01 B∗14:02; B∗40:01 C∗03:04; C∗08:02 | Pos. | Pos. |
| 199 | M | 23 | vsAA | Initial diagnosis | None | A∗01:01; A∗68:02 B∗08:01; B∗14:02 C∗07:01; C∗08:02 | Pos. | Pos. | |||
| 200 | F | 58 | sAA | Initial diagnosis | None | A∗26:01; A∗31:01 B∗40:02; B∗55:01 C∗01:02; C∗03:04 | Pos. | Pos. | |||
| 213 | M | 40 | vsAA | Relapse after ATG + CsA | None | A∗02:05; A∗31:01 B∗18:01; B∗50:01 C∗06:02; C∗07:01 | Pos. | Pos. | |||
| 219 | M | 62 | mAA | Relapse after CsA + Epag | CsA | 10 | Relapse after CsA | CsA | A∗26:01; A∗66:01 B∗07:02; B∗40:02 C∗07:02; C∗15:02 | Pos. | Pos. |
| 222 | F | 56 | vsAA | Initial diagnosis | None | A∗03:01; A∗24:02 B∗07:02; B∗55:01 C∗03:03; C∗07:02 | Pos. | Pos. | |||
| 227 | M | 76 | vsAA | Initial diagnosis | None | A∗02:01; A∗03:01 B∗07:02; B∗35:01 C∗04:01; C∗07:02 | Pos. | Pos. | |||
| 228 | M | 27 | vsAA | Initial diagnosis | None | 17 | CR after ATG + CsA + Epag | CsA | A∗02:01; A∗03:01 B∗07:02; B∗51:01 C∗07:02; C∗14:02 | Pos. | Pos. |
| 230 | M | 66 | mAA | Initial diagnosis | None | 5 17 | Refractory to CsA PR after Danazol | CsA + Epag Danazol + CsA | A∗02:01; A∗03:01 B∗07:02 C∗07:02 | Pos. | Pos. |
| 232 | M | 53 | mAA | Refractory to CsA + Epag | None | A∗02:01; A∗11:01 B∗07:02; B∗08:01 C∗07:01; C∗07:02 | Pos. | Neg. | |||
| 257 | F | 48 | mAA | PR after ATG + CsA | CsA + Epag | A∗02:01; A∗33:01 B∗14:02; B∗51:01 C∗02:02; C∗08:02 | Pos. | Pos. | |||
| Patient . | Sex . | Initial sampling . | Follow-up . | HLA-class I . | EBV IgG . | CMV IgG . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (y) . | Diagnosis . | Disease state . | Current treatment . | Time after initial sample (mo) . | Disease state . | Current treatment . | |||||
| 105 | M | 19 | mAA | PR after ATG + CsA | CsA + Epag | A∗24:02 B∗07:05; B∗51:01 C∗03:04; C∗15:05 | Pos. | Neg. | |||
| 144 | M | 57 | sAA | Relapse after ATG | CsA + Epag | A∗02:01; A∗03:01 B∗07:02; B∗51:01 C∗02:02; C∗07:02 | Pos. | Pos. | |||
| 191 | F | 69 | sAA | Relapse after ATG + Epag | CsA + Epag | 18 | Relapse | CsA + Epag | A∗24:02 B∗07:02 C∗07:02 | Pos. | Pos. |
| 192 | M | 56 | mAA | Relapse after CsA + Epag | Epag | A∗02:01; A∗32:01 B∗07:02; B∗40:02 C∗02:02; C∗07:02 | Pos. | Neg. | |||
| 198 | F | 48 | vsAA | Initial diagnosis | None | 20 | CR | CsA | A∗02:01; A∗33:01 B∗14:02; B∗40:01 C∗03:04; C∗08:02 | Pos. | Pos. |
| 199 | M | 23 | vsAA | Initial diagnosis | None | A∗01:01; A∗68:02 B∗08:01; B∗14:02 C∗07:01; C∗08:02 | Pos. | Pos. | |||
| 200 | F | 58 | sAA | Initial diagnosis | None | A∗26:01; A∗31:01 B∗40:02; B∗55:01 C∗01:02; C∗03:04 | Pos. | Pos. | |||
| 213 | M | 40 | vsAA | Relapse after ATG + CsA | None | A∗02:05; A∗31:01 B∗18:01; B∗50:01 C∗06:02; C∗07:01 | Pos. | Pos. | |||
| 219 | M | 62 | mAA | Relapse after CsA + Epag | CsA | 10 | Relapse after CsA | CsA | A∗26:01; A∗66:01 B∗07:02; B∗40:02 C∗07:02; C∗15:02 | Pos. | Pos. |
| 222 | F | 56 | vsAA | Initial diagnosis | None | A∗03:01; A∗24:02 B∗07:02; B∗55:01 C∗03:03; C∗07:02 | Pos. | Pos. | |||
| 227 | M | 76 | vsAA | Initial diagnosis | None | A∗02:01; A∗03:01 B∗07:02; B∗35:01 C∗04:01; C∗07:02 | Pos. | Pos. | |||
| 228 | M | 27 | vsAA | Initial diagnosis | None | 17 | CR after ATG + CsA + Epag | CsA | A∗02:01; A∗03:01 B∗07:02; B∗51:01 C∗07:02; C∗14:02 | Pos. | Pos. |
| 230 | M | 66 | mAA | Initial diagnosis | None | 5 17 | Refractory to CsA PR after Danazol | CsA + Epag Danazol + CsA | A∗02:01; A∗03:01 B∗07:02 C∗07:02 | Pos. | Pos. |
| 232 | M | 53 | mAA | Refractory to CsA + Epag | None | A∗02:01; A∗11:01 B∗07:02; B∗08:01 C∗07:01; C∗07:02 | Pos. | Neg. | |||
| 257 | F | 48 | mAA | PR after ATG + CsA | CsA + Epag | A∗02:01; A∗33:01 B∗14:02; B∗51:01 C∗02:02; C∗08:02 | Pos. | Pos. | |||
On treatment indicates whether the patient was on treatment at the time of sample acquisition.
ATG, antithymocyte globulin; CR, complete response; CsA, cyclosporin A; Epag, eltrombopag; F, female; IgG, immunoglobulin G; M, male; mAA, moderate aplastic anemia; Neg., negative; PR, partial response; Pos., positive; sAA, severe aplastic anemia; vsAA, very severe aplastic anemia.